Yale University

EliScholar – A Digital Platform for Scholarly Publishing at Yale
Yale School of Nursing Digital Theses

School of Nursing

January 2021

Creating An Integrated Opioid Policy For Multi-State Hospice
Practices: Improving Opioid Compliance And Patient Safety
Manjeet Kaur
write2rosy@yahoo.com

Follow this and additional works at: https://elischolar.library.yale.edu/ysndt

Recommended Citation
Kaur, Manjeet, "Creating An Integrated Opioid Policy For Multi-State Hospice Practices: Improving Opioid
Compliance And Patient Safety" (2021). Yale School of Nursing Digital Theses. 1115.
https://elischolar.library.yale.edu/ysndt/1115

This Open Access Thesis is brought to you for free and open access by the School of Nursing at EliScholar – A
Digital Platform for Scholarly Publishing at Yale. It has been accepted for inclusion in Yale School of Nursing Digital
Theses by an authorized administrator of EliScholar – A Digital Platform for Scholarly Publishing at Yale. For more
information, please contact elischolar@yale.edu.

CREATING AN INTEGRATED OPIOID POLICY FOR MULTI-STATE HOSPICE
PRACTICES: IMPROVING OPIOID COMPLIANCE AND PATIENT SAFETY

Submitted to the Faculty
Yale University School of Nursing

In Partial Fulfillment
of the Requirements for the Degree
Doctor of Nursing Practice

Manjeet Kaur
March 31, 2021

i

© 2020 by Manjeet Kaur
All rights reserved.

ii

This DNP Project is accepted in partial fulfillment of the requirements for the degree
Doctor of Nursing Practice.

Mary Ann Camilleri JD BSN RN FACHE
Signed: ___________________________________________
April XX, 2021

iii

This material is protected by Copyright Law (Title 17, US Code). Brief quotations are allowable
without special permission, provided that accurate acknowledgement of source is made.
Requests for permission for extended quotation from or reproduction of this manuscript in whole
or in part must be granted by the copyright holder.

Manjeet Kaur BSN RN MPH MS CPHQ
March 31, 2021

iv

Acknowledgements
I would like to thank my husband, without his support this would not have been possible;
my son and my daughter for their steadfast cheering; and
my mother who gave me the gift of becoming a nurse.
To my Advisors, Prof. Mary Ann Camilleri and Dr. Joan Kearney, for their valuable guidance
and constant encouragement.
Lastly, to my father who taught me true meaning of caring and my (late) father-in-law, who
taught me value of patience and perseverance in life.

v

Abstract
End of life (EOL) symptom management is the cornerstone of hospice care. Hospice patients,
especially advanced cancer patients, have an increased need for pain and symptom management
towards end of life. For those patients at EOL, opioids are the mainstay treatment to relieve
intractable and breakthrough pain. Due to opioid regulatory changes over the past few years,
there has been more confusion than clarity among the hospice & palliative care practitioners
prescribing opioids for EOL pain management. Healthcare practices across the country are
realigning their policies to the opioid prescription rule changes. It is imperative for hospice
providers to translate federal and state opioid regulations into organizational policy to guide
hospice & palliative care practice. The purpose of this project was to review, synthesize and
reconcile federal, state, and local opioid regulations and create a system for a sustainable data
base in order to develop and maintain opioid policies for implementation in multi-site hospice
organization, across 35 states, to ensure ongoing compliance with opioid laws. The cyclic
process of the KTA framework was used for the project that places creators and users within a
system which is dynamic as well as adaptive, so that as the opioid regulations change, the policy
and protocols will be modified and re-adopted. An umbrella opioid medication policy, and state
specific guidance was developed. Results show that, 4 weeks after policy dissemination, 32 out
of 35 states continued to maintain 100% clinician compliance with the umbrella opioid
medication policy, and state specific guidance. There was a 50% reduction in opioid-related
events. This DNP project has applicability to further compliant opioid practice in a variety of
care settings nationwide.
Keywords: End of life, Hospice, Opioid, Pain, Regulatory Compliance.
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Creating an integrated opioid policy for multi-state hospice practices: improving opioid
compliance and patient safety
CHAPTER 1
Introduction
End of life (EOL) symptom management is the cornerstone of hospice care. Hospice
patients, especially advanced cancer patients, have an increased need for pain and symptom
management towards end of life. Increasingly, care of advanced cancer patients, palliative or
hospice care, is being moved to ambulatory care settings, making it even more challenging to
manage the symptoms of dying patients . For those patients at EOL, opioids are the mainstay
treatment to relieve intractable and breakthrough pain. Due to opioid regulatory changes over the
past few years, there has been more confusion than clarity among the hospice & palliative care
practitioners prescribing opioids for EOL pain management. Healthcare practices across the
country are realigning their policies to the opioid prescription rule changes. It is imperative for
hospice providers to translate federal and state opioid regulations into organizational policy to
guide hospice & palliative care practice.
Background
Uncontrolled pain is one of the most debilitating symptoms at EOL which affects 50% of the
patients in their last month of life (Dy, 2016). Pain is defined as an unpleasant sensory and
emotional experience associated with actual or potential tissue damage, or described in terms of
such damage (IASP, 2017). Acute pain is defined as the pain that comes on quickly, can be
severe, but lasts a relatively short time, such as days to less than a few months. Chronic pain is
defined as the pain that can range from mild to severe, and persists or progresses over a long
period of time, such as over 3 months to several years. Breakthrough pain is a sudden increase in
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pain that may occur in patients who already have chronic pain from cancer, arthritis,
fibromyalgia, or other conditions. It usually lasts for a short time, but the level of pain may be
severe. Breakthrough pain is usually not a symptom of a new condition or a condition that has
gotten worse. It is also called pain flare (NCI, n.d.).
A recent review of patient safety and end of life reports that common safety issues in
hospice and palliative care include inappropriate pain medications and inadequate pain
management (Dy, 2016). Hospice patients have an increased need for pain and symptom
management towards end of life. An additional challenge, especially for hospice providers, is
breakthrough pain in cancer patients toward end of life. This sudden eruption of severe pain in a
patient whose pain is otherwise adequately controlled on a long-acting pain medication can
interrupt a terminally ill patient’s daily life causing physical & psychological stress due to
increased health burden, loss of independence and disrupted autonomy (Katz, Gajria, Shillington,
Stephenson & Harshaw, 2017) leading to a decline in quality of life.
The goal of hospice is to provide comfort to the patient. Opioids are the mainstay treatment
to relieve distressing EOL symptoms, such as intractable nausea and vomiting, dyspnea, cancer
pain, and delirium. In a systematic review(Brant, Rodgers, Gallagher, & Sudaramurthi, 2017), it
was found that opioids are the most effective and safe evidence-based pharmacologic treatment
for adequate management of breakthrough cancer pain. Opioids are a substance used to treat
moderate to severe pain. Opioids are like opiates, such as morphine and codeine, but are not
made from opium. Opioids bind to opioid receptors in the central nervous system and block pain
messages from body to the brain (NCI, n.d.). In spite of increasing regulatory scrutiny of opioid
prescriptions and use, opiates are desirable and effective options for managing physical pain in
terminally ill patients (Albert, 2017).
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History of Opioid Prescription in United States
Pain treatment in the United States (U.S.) has evolved over the years. In later part of the 19th
century morphine was used to treat pain symptoms in those injured in Civil War. Similarly,
anesthetics and analgesics were prescribed to manage pain in war veterans during early 20th
century (Bernard, Chelminski, Ives, & Ranapurwala, 2018). In the last 50 years, the U.S. has
seen a progressive increase in opioid prescriptions. During the 70s, physicians were trained to
order minimal opioids for pain, and nurses were trained to give minimum dose of prescribed
opioids, often less than the prescribed dose. Unless death was imminent, a patient’s pain was
undertreated and poorly managed. In the following decade, studies done on small groups of
patients, mainly inpatient, suggested use of opioids for pain control in chronic cancer and noncancer patients. These studies deemphasized the risk of addiction to prescription opioids. There
was no long-term study of effects of opioids and no published data on use of opioids for chronic
pain (Meldrum, 2016). Around the same time, World Health Organization (WHO) recommended
opioids for treating cancer pain and for pediatric chronic noncancer pain (Scholten, Christensen,
Olesen, & Drewes, 2019).
By the 1990’s there was a rise in opioid prescriptions. Controlled substances were ordered
not only to manage acute pain after surgery, pain in advanced cancers and pain in patients who
were terminally ill, but also to manage intractable and chronic pain. In the same decade,
pharmaceutical companies caught on to the idea of mass producing and promoting opioids. There
was a widespread perception that prescription opioids were not addictive. Due to the American
Pain Society’s designation of pain as the fifth vital sign and recommendation to physicians to
aggressively manage patient’s pain, the physician practices experienced a surge in opioid
prescriptions. The health insurance companies provided good coverage of patient’s opioid
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prescription but rather poor coverage of non-pharmacologic approaches to pain management,
such as physical therapy. Lack of health insurance coverage led to more patients using opioid
prescriptions to manage pain (DeWeerdt, 2019).
As the movement to manage pain better gained momentum, the sale of prescription opioids
increased in the 1990s, and quadrupled between 1999 to 2010. There was an increase in nonprescription and illegal opioid use seen parallel to the prescription opioid increase (Bonnie,
Schumacher, Clark, & Kesselheim, 2019). Drug companies, such as Purdue Pharma, did
aggressive marketing of opioids as safe for long-term use. Due to abundant opioid prescriptions,
there was an increase in scheduled substances available to the public in their homes, which
resulted in misuse, drug diversion and illegal sale. An increasing number of patients became
addicted to opioids and there was an increase in drug-seeking behavior. Patients changed
providers, pharmacies, and sometimes their hometown to gain a prescription for opioids, either
for personal use or to sell on the streets for a higher price. Those who could no longer afford or
were denied a prescription, took to drug traffickers and cheap street drugs to fulfil their addiction
needs. The years 2000-2014 saw an alarming 137% increase in controlled substance overdoses
and a 200% increase in overdose deaths (Meldrum, 2016).
Opioid Guidelines in the United States
Mild to moderate pain can be effectively managed with non-opioid analgesics, however
stronger pain medications are needed to manage severe pain. Many cancer patients live with
moderate to severe pain throughout their life, either due to nature of their disease or due to longterm effects of cancer treatment. Cleary, Gelband and Wagner (2015) explain that cancer pain
equally affects the rich and the poor, especially toward the end of life. So, the use of “opioids—
such as codeine and morphine—are invariably needed toward the end of life” (Cleary, Gelband,
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& Wagner, 2015, p. 166). Because of this, international and national guidelines and
recommendations continue to vouch for a need of opioids to manage cancer and terminal pain.
The World Health Organization (WHO) recommends opioid agonists for moderate to severe
cancer pain. Opioid medications such as morphine have been included in the WHO Model List
of Essential Medicines for adults since 2002, and for children since 2007 (WHO, September,
2019; WHO, 2019). Additionally, to treat pediatric patients, “several other opioid agonists are
included in the WHO Guidelines on the Pharmacological Treatment of Persisting Pain in
Children” (Duthey & Scholten, 2013, p. 284). Effective pain and symptom control in end-of-life
care can allow patients to progress through the dying process in a safe, dignified, and
comfortable manner. The Centers for Disease Control and Prevention (CDC) released guidelines
for prescribing opioids to treat chronic pain outside of active cancer, palliative, & end-of-life
care. The CDC defines chronic pain as a condition lasting more than 3 months or past the normal
healing of tissue injury. The purpose of these guidelines is to improve opioid prescription
practice for safe and effective pain treatment, and to reduce harm to the patient (CDC, 2019).
Similarly, the U.S. Department of Health and Human Services (HHS) recommends and
offers opioid & pain management education for medical professionals. HHS recognizes medical
professional’s role in safe prescription and management of opioids. When prescribing opioids,
HHS recommends assessing risk to the patient, educating patients, and co-prescribing naloxone.
Naloxone is an “opioid-antagonist” that is used to treat opioid overdose. It is used to “counteract
life-threatening depression of the central nervous system and respiratory system” (Harm
Reduction Coalition, n.d., para 1) so that person can begin to breathe normally. If administered
on time, naloxone can temporarily reverse opioid effects and prevent overdose death (SAMHSA,
2018).
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The National Hospice & Palliative Care Organization, National Association for Home Care
& Hospice, and American Academy of Hospice and Palliative Medicine continue to emphasize
importance of pain management in palliative and EOL patients. Additionally, these national
organizations recommend and offer continued training and education to medical professionals on
pain management, safe opioid prescribing, and opioid risk mitigation when prescribing opioids to
patients during palliative and EOL care.
Problem Statement
The current state of the opiate epidemic has caught regulators’ attention. There has been
development of new federal and state-level interventions to guide opioid prescription and
disposal practice. During site surveys, hospice accrediting bodies, and federal and state surveyors
specifically review hospice operations’ compliance with those rules. To assure safe opioid
treatment to patients, and to stay compliant with federal and state regulations, hospice operators
must align their policies with national and local rules. As per the WHO 2018 report, “clinical and
policy guidelines should be complementary in order to increase overall access to controlled pain
relief medicines” (WHO, 2018, p. 23). There are federal as well as state opioid regulations.
However, state opioid regulatory changes are not standardized across all state lines. Hospice
providers need a detailed review of federal and state-level opioid regulations and practice rules to
develop or revise opioid prescription and disposal policies and protocols. There was no one
professional society, organization, website, or hospice practice that has federal and all U.S.
state’s opioid regulatory data. An opioid regulation and practice rule data repository was needed
to house the federal and state rules at one central location. The data was collected from literature
review, professional and national organizations, and federal and state legislatures. This
regulatory data repository can provide ready access to federal and state opioid rules and
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regulations for a systematic review. A detailed review of this regulatory data can help develop an
opioid policy for hospice clinicians. This opioid policy can further inform hospice practice
protocols for standardization of care. Implementation of informed policy and protocol can assure
regulatory compliance and medico-legal fortitude for a multi-state healthcare organization.
Significance of Addressing the Problem
Healthcare in the United States is complex and heavily regulated. Hospice practice is no
exception. Federal and state authorities publish rules and directives that guide health industry
operations and impact clinical practice. The Centers for Medicare and Medicaid, the Health
Insurance Portability and Accountability Act, the United States Drug Enforcement
Administration (DEA), and the U. S. Food and Drug Administration are a few of the many
federal regulatory authorities impacting hospice practice. In addition, each state may have
hospice rules, drug rules, and state practice acts that guide hospice operations. To develop policy
and practice protocols, a multi-state hospice organization needs to review federal as well as state
guidelines across the state lines. Hospice providers have to sift through this web of rules and
regulations to provide safe and compliant patient care.
The nation is currently going through a major opioid epidemic. Providers across the country
are trying to keep up with the changing landscape of federal and state opioid rules. Hospice
providers (physicians and nurse practitioners) prescribe opioids to hospice patients and monitor
patients for pain and symptom relief. A lack of a central opioid regulation repository makes it
cumbersome and challenging to search through a myriad of resources to develop an informed
policy. That’s why developing an opioid regulatory catalog containing the most pertinent and
relevant rules and statutes is the first logical step toward an informed organization-wide policy.
Also, currently there’s no review of opioid rules and regulations literature available for
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systematic policy development. That’s why a thorough review of opioid regulations and statutes
is the next logical step in policy development. A qualitative analysis of opioid rule data will
identify opioid guideline themes in favor of, neutral to, or not in favor of hospice practice. The
themes will guide the development of hospice policies and practices for the prescribers. To
comply with federal and state opioid regulatory requirements, an up-to-date policy can be a
reliable source to guide development of clinical practice protocols. A lack of federal and state
opioid regulations review may misinform policy development, cause noncompliance with
published rules, risk regulatory authority scrutiny, and compromise patient care.

CREATING AN INTEGRATING POLICY

9

CHAPTER 2
Review of the Literature
A review of the literature for current state of opioid regulatory changes and policies to guide
safe patient practices was conducted (Appendix A). A search was conducted using the
Cumulative Index of Nursing and Allied Health Literature (CINAHL), PAIS Index, and Ovid
Medline databases using the following keywords: end of life, palliative care, hospice, pain
management, cancer pain, opioid, policy, rules, standards, recommendations, practices,
prescribe, overdose, addiction, naloxone, toolkit, and repository. In addition to the keywords,
three Boolean operators were used for the search: and, or, and not. The search yielded 419
scholarly articles of which 19 were reviewed. Articles supporting evidence for opioids used in
end of life and cancer pain were included in the review. Literature was excluded if the article did
not include opioid use in pain management.
Resources also included relevant federal, state, and local agencies and professional
organizations for guidelines, such as the Centers for Disease Control and Prevention, the
International Association for the Study of Pain, the National Conference of State Legislators, the
National Science and Technology Council, the National Cancer Institute, the Prescription drug
abuse policy system, the Substance Abuse and Mental Health Services Administration , the U.S.
Department of Health and Human Services, and the World Health Organization. The literature
review provided insight into the current opioid crisis in the United States, and federal and state
strategies to address this opioid crisis.
Current Opioid Crisis
The beginning of the 21st century saw a rise in strategies to better manage pain in
Americans, including recognizing pain as the fifth vital sign. In the year 2000, Veterans’ Health
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Administration established protocols throughout the system to routinely screen and assess pain in
patients. The strategy was that patients were not to be denied analgesics due to fear of addiction
or side effects. In 2001, the Joint Commission released pain management accreditation standards
for ambulatory, inpatient as well as home care providers. The standards recognized and
recommended that pain assessment and management is a patient’s right. This was a paradigm
shift towards accepting patient’s subjective reporting of pain over the ill effects of opioids. The
physicians found failing to adequately treat a patient’s pain were disciplined, fined, or
sanctioned. Medical boards were addressing complaints of inadequate prescribing to manage
patient’s pain and, in litigation against physicians undermanagement of patient’s pain was
considered neglect. In 2004, the Federation of State Medical Boards policy advised state medical
boards that overtreatment and undertreatment of pain were both equally considered a violation of
the standard of care (Garcia, 2013).
As the philosophy of pain management and perception of painkiller prescriptions shifted, the
quantity of prescription opioids sold to pharmacies, hospitals, and medical clinics steadily and
sharply increased between 1999 and 2010. The health insurance payors saw a cost saving in
restricting reimbursement for non-pharmacologic interventions for pain management, such as
physical therapy, cognitive-behavioral therapy, and complementary and alternative medicine
(Tompkins, Hobelmann, & Compton, 2017). The number of pain management clinics focusing
on pain treatment through opioid prescription increased and primary care practitioners prescribed
opioids without education or warning patients of the risk of addiction. The increased use of
prescription controlled substances led to abundant availability of opioids in the community. This
in turn led to a rise in opioid misuse, abuse, diversion, nonmedical use, and overdoses. The
opioid addicted nonmedical users turned up at emergency departments to fulfill their needs. The

CREATING AN INTEGRATING POLICY

11

nonmedical prescription opioid use is costing American insurers approximately $72.5 billion
annually (Garcia, 2013). Those who couldn’t afford a prescription painkiller took to the streets to
buy cheaper versions of the opioids. This gave rise to an illicit drug market where drugtraffickers reached the American middle-class (Meldrum, 2016).
The United States is thus facing an opioid crisis caused by opioid practices from the past
three decades. The opioid epidemic has equally impacted all ages, gender, and every
socioeconomic group in the United States (Bonnie, Ford, & Phillips, 2017). No corner of the
country is untouched by the ill effects of the opioid epidemic.

Figure 1. Drug Overdose Deaths in the U.S. Involving Opioids, 1999 to 2018. Source: National
Center for Health Statistics WONDER (1999-2016) and Provisional Drug Overdose Death
Counts (2017-2018), National Vital Statistics System, Mortality, National Science & Technology
Council. Retrieved from https://www.whitehouse.gov/wp-content/uploads/2019/10/HealthResearch-and-Development-for-Opioid-Crisis-National-Roadmap-2019.pdf December 2019.

CREATING AN INTEGRATING POLICY

12

Between 1999 and 2010, the number of opioid prescriptions sold quadrupled and
prescription painkiller overdose deaths tripled. By 2018, the overdose deaths from prescription &
illicit opioid use had reached 42,250, an alarming level of five times the 8,050 overdose deaths in
the year 1999 (NSTC, 2018) (Figure 1). Meldrum (2016) brings attention to “an alarming
increase in heroin use across the country and an epidemic of drug overdose deaths, which
increased 137% between 2000 and 2014; overdoses involving prescription opioids and heroin
increased 200% in that period” (p. 1366). Children born to opioid users experienced opioid
withdrawal. The opioid crisis had now extended from families to communities in the United
States (NSTC, 2018). In 2017, under President Trump’s direction, HHS Secretary Eric D.
Hargan declared the opioid crisis a public health emergency in the U.S. (HHS, 2017).
Federal Strategies to Address the Opioid Crisis
CDC recognizes that long-term opioid use in noncancer nociceptive and neuropathic pain
presents a serious risk to the patient and adds the burden of managing the prescription use to the
primary care practices. In 2016, the CDC released opioid guidelines for primary care providers.
In the guidelines, the CDC has opioid prescribing recommendations to treat chronic pain in
outpatient settings. The rationale of these guidelines is to improve primary care provider
knowledge and opioid prescribing practices to safely manage patient’s pain in an outpatient
setting. The CDC guidelines clarify that active cancer treatment, palliative care, and end- of-life
care opioid prescribing is excluded from these guidelines (Dowell, Haegerich, & Chou, 2016).
The CDC released an advisory statement in April 2019 clarifying the scope of application of
2016 CDC opioid prescription guidelines. The guidelines are not intended for patients in active
cancer treatment, patients experiencing acute sickle cell crises, patients experiencing post-
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surgical pain, patients who already prescribed a higher dosage (≥90 MME/day) of opioids, or for
use in patients on medication-assisted treatment for opioid use disorder (CDC, 2019).
On March 19, 2018, President Trump declared his plan to fight the opiate crisis with priority
to “improve access to prevention, treatment, and recovery support services; target the availability
and distribution of overdose-reversing drugs; strengthen public health data reporting and
collection; support cutting-edge research on addiction and pain; and advance the practice of pain
management” (HHS, 2017, para 7). As a result, Congress funneled more funds in the fiscal year
2019 budget to assist federal, state, and community organizations to combat the opioid crisis
through opioid addiction prevention and treatment programs; overdose, reversal, and recovery
policies; and research and development. This funding can expand coverage through the
Affordable Care Act to assist in increasing existing addiction treatment benefits for the uninsured
(Hahn, 2018). The changes in federal policy have fueled initiatives to address and drastically
change current opiate treatment projects and policies for both practitioners and patients. The
interventions for patient safety include Centers for Disease Control guidelines for prescribing
opioids for chronic pain, Prescription drug monitoring programs (PDMPs), naloxone for opiate
overdose emergencies, and expansion of medication assisted treatment (MAT) (Painter, 2017;
McGinty et al., 2018).
The Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for
Patients and Communities Act or the SUPPORT for Patients and Communities Act was enacted
in 2018. Despite differences among Democrats and Republicans on many policies of national
interest, the SUPPORT for Patients and Communities Act received bipartisan support. Under
SUPPORT for Patients and Communities Act, there are provisions to address the opioid crisis
and patient safety for Medicaid, Medicare, and other health insurance enrollees, including mental
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health parity for substance use disorder (SUD), safe disposal of unused medication provision for
hospice providers, provisions for emergency departments, empowering pharmacists and
prescribers by developing opioid prescribing and dispensing best practices. The act has
provisions for grants for peer support communities of recovery and regional centers for SUD
education (S. 2680, 2018).
Additionally, under the SUPPORT Act, there is a provision for expansion of existing
programs to address the opioid crisis – expanding access to telehealth and federal reimbursement
for SUD, incentives for prescribing opioid alternatives, and empowering the providers to use
MAT for effectively treating SUD and sustaining recovery (McCullough, 2018). Successful and
uniform implementation of the Mental Health Parity and Addiction Equity Act, and its alignment
to evidence based federal, state, and community level opiate treatment programs depends on –
collaboration and communication among stakeholders and agencies, creation and standardization
of education materials and clinical tools, and state evaluation of the practices and operations of
an insurer (Painter, 2017).
In the Substance Abuse and Mental Health Services Administration (SAMHSA) opioid
overdose prevention toolkit, one of the strategies recommended to prevent overdose death is
ensuring ready access to naloxone. Naloxone is not an addictive medication and thus has no
abuse potential; it only works in the body if an opioid is present otherwise it has no effect on the
body. Another benefit of naloxone is that it can be injected or administered intranasally with
equal ease either by trained medical professional or by layperson.

CREATING AN INTEGRATING POLICY

15

Figure 2. Does the jurisdiction have a naloxone access law? Reprinted from National institute on
drug abuse’ Prescription drug abuse policy system (PDAPS). Retrieved from
http://pdaps.org/datasets/laws-regulating-administration-of-naloxone-1501695139 December
2019.
Ease of use makes it an ideal medication to use in a prescription opioid as well as heroin
overdose (Harm Reduction Coalition, n.d.). Moreover, it is available at pharmacy stores at low or
no cost (SAMHSA, 2018). The national naloxone initiative to reverse an opioid overdose is
currently operating in all 50 states and supports the use of naloxone for opiate overdose
emergencies (SAMHSA, 2017) (Figure 2).
State Strategies to Address the Opioid Crisis
State regulatory bodies are addressing the opioid overdose crisis through policy and
regulatory efforts. State legislators establish regulations, and state regulatory bodies such as, the
health department or the state licensing authority, implement and enforce those regulations.
States are addressing opioid overdose issues, inappropriate opioid prescription issues, and safe
opioid prescribing by establishing prescription drug monitoring programs (PDMPs), regulating
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pain clinics, and establishing opioid dosage thresholds (Garcia, 2013). Also, states are addressing
the complexity of the opioid crisis by imposing regulatory requirements in addition to enforcing
federal laws (Garcia, 2013).
Prescription drug monitoring programs. PDMPs are state administered centralized
electronic databases to track opioid prescriptions. The database enables prescribers and
pharmacies to screen and monitor history of patient’s prescription medication use. The database
facilitates recognizing potential prescription medication abuse or diversion. PDMPs empower
state regulatory bodies to monitor prescribers inappropriate prescribing and pharmacies
inappropriate dispensing behaviors.

Figure 3. Does this state have legislation authorizing a PDMP? Reprinted from National institute
on drug abuse’ Prescription drug abuse policy system (PDAPS). Retrieved from
http://pdaps.org/datasets/prescription-monitoring-program-laws-1408223428-1502818371.
December 2019.
Currently, 49 states and District of Columbia have mandatory PDMP laws (Figure 3). The
state of Missouri is the only state that has not been able to pass the PDMP bill through its state
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senate seven years in a row (Howell, 2017; Weber, 2019). The mandatory PDMP enrollment law
requires prescribers and pharmacies to enroll in to access the database. In addition, the
mandatory PDMP query laws require prescribers and pharmacies to check their state’s PDMPs
prior to prescribing opioids. PDMP law prevents doctor shopping and rogue physician
prescribing practice (Painter, 2017; McGinty et al., 2018; Garcia, 2013).
Regulating pain clinics. As shown in figure 4 below, as of May 2018, 12 states have
enacted some kind of pain management clinic law (PDAPS, 2019) (Figure 4). These laws
regulate the clinic’s protocols, physician prescribing practices, and owner accountability.

Figure 4. Is there a pain management clinic law? Reprinted from National institute on drug
abuse’ Prescription drug abuse policy system (PDAPS). Retrieved from
http://pdaps.org/datasets/pain-management-clinic-laws December 2019.
The difference between a legitimate pain management clinic, and a “pill-mill” pain clinic is
their prescription practice. The pain management clinics treat and manage patient’s chronic pain
and prescribe a controlled substance to the majority of their patients. These clinics have a
licensed physician trained in safe pain management practices providing oversight to the program.

CREATING AN INTEGRATING POLICY

18

The other licensed providers at these clinics are also trained in safe pain management practices,
including recognizing signs of addiction & diversion. These clinics are usually affiliated with a
hospital or a larger health care system. The “pill-mill” pain clinics, on the other hand, are mostly
run by private owners who are not medically trained. The purpose of these clinics is maximizing
patient volume to maximize profit. These clinics do not institute legitimate pain management
practice, operate cash-only, refer all their patients to one diagnostic facility, and prescribe
identical opioid prescription to all patients. (Garcia, 2013).
Establishing Dosage Thresholds. Since the release of CDC opioid guidelines in 2016,
states have been considering opioid policy revisions. As of October 2018, >30 states have
enacted laws setting limits on opioid prescriptions. The CDC guidelines for prescribing opioids
recommend cautious opioid prescription dosages for safe and more effective pain treatment.
Prescribing lowest effective dosage and titrating up or tapering down based on individual
benefits helps keep a close watch on the patient. The CDC recommendation is to weigh in
individual risk when increasing dosage to ≥50 morphine milligram equivalents (MME)/day, and
to avoid increasing dosage to ≥90 MME/day. However, the guidelines recommend that the
clinician should carefully consider rationale & effects if dosage needs to be titrated to ≥90
MME/day (CDC, 2019).
To control the quantity of opioids prescribed and dispensed in the community, states have
enacted laws restricting opioid prescription to a certain number of days of supply (Figure 5).
These restrictions are mostly for first-time opioid prescriptions and allowed number of days of
supply ranges from 3 days to 14 days. Some states specify that these restrictions are for
managing acute pain, and provide exceptions for chronic, cancer, palliative, and hospice patients.
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Many state laws have provisions to allow for exceptions for patients who are receiving
medication-assisted treatment (MAT) for substance-use disorder (SUD) (NCSL, 2019).

Figure 5. Laws setting limits on certain opioid prescriptions. Reprinted from National conference
on state legislatures (NCSL). Retrieved from http://www.ncsl.org/research/health/prescribingpolicies-states-confront-opioid-overdose-epidemic.aspx December 2019.
In addition to setting initial opioid prescription limits for adult patients, Alaska, Connecticut,
Indiana, Louisiana, Massachusetts, Nebraska, Pennsylvania and West Virginia have also set
opioid prescription limits for minors. Additionally, these state regulations require opioid
education, including discussing opioid risks and side effects, with minor patients and their adult
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caregivers. In contrast, states such as New Hampshire, Ohio, Oregon, Vermont, Virginia,
Washington and Wisconsin have not enacted the opioid prescription limit statute. They direct
other state regulatory authorities, such as the health department or board of medicine to institute
opioid prescribing limits (NCSL, 2019).
“Overdose Good Samaritan” immunity laws related to naloxone use protect drug users who
call for emergency assistance in the event of a drug overdose and may seek addiction recovery
treatment after naloxone administration. Access to naloxone for overdose reversal is dependent
on state policies which are not aligned across all states, and not all of the states have passed
overdose Good Samaritan Law (PDAPS, 2019; SAMHSA, 2017) (Figure 6).

Figure 6. Does the jurisdiction have a drug overdose Good Samaritan Law? Reprinted from
National institute on drug abuse’ Prescription drug abuse policy system (PDAPS). Retrieved
from http://pdaps.org/datasets/good-samaritan-overdose-laws-1501695153 December 2019.
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While Overdose Good Samaritan immunity laws vary by state, they all consider either
decriminalizing or mitigating actions for possession and use of drugs (SAMHSA, 2017).
Enactment of this law is a step towards lifting the stigma and changing the thought process that
opioid misuse is a choice. Also, separating the drug user laws from drug seller laws is
appreciated by lawmakers and the public. Spotlight on the opioid misuse issues has changed
policymakers’ perceptions and fostered an understanding that opioid misuse is a medical
condition in need of treatment (Johnson, 2018; Saunders, Jarlenski, Levy, & Kozhimannil,
2018).
Along with instituting new opioid policies, states have revised and remodeled existing laws
and policies (Parker, Strunk, & Fiellin, 2018). On a community level, syringe exchange
programs are one such comprehensive strategy to address the health of people with SUD.
Currently, 41 states have syringe exchange programs. These programs promote prevention of
drug-related transmission of infections by providing access to free sterile syringes and needles,
and safe disposal of used syringes and needles. Syringe exchange programs are providing much
needed resources for the community by targeting high-risk areas (Painter, 2017). Reforms in
opioid prescribing practices will help prevent substance abuse, diversion and overdose, while
ensuring legitimate access to pain management. Opioid prescribing cap laws limit the number of
days’ supply and/or dose of prescribed opioids. Pill mill laws strictly regulate pain management
clinics to prevent rogue clinics (pill mills) from issuing opioid prescriptions without medical
indication or necessity (Mcginty et al., 2018).
Literature Gap
Since the 2016 release of CDC opioid prescription guidelines, there has been a flood of
opioid related laws and policies being enacted at the federal as well as the state level. These
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opioid prescription laws are not uniform across all the states, and not all states have an opioid
prescription law. Most federal and state opioid regulations have provisions to exempt cancer,
palliative care and hospice patients, but not all. While bipartisan efforts to curb the opioid
epidemic continue at all levels, disparity remains among states regarding opioid policies (Painter,
2017). Fear surrounding inappropriate use of opioids and an increase in opioid related
regulations have caused unintended consequences for the hospice patients (Fehlberg, Broyles,
Wu, & Halpern, 2018). Due to fear of being scrutinized by the state regulatory authority or a
state professional board, physicians are prescribing minimum dosage of opioids. By prescribing a
minimum dosage, the prescriber doesn’t have to deal with opioid risk mitigation required when
prescribing higher dosage of opioids to the patient. Even when the controlled substance is
prescribed to a hospice patient, pharmacies in many states are restricting quantity of medication
dispensed to the minimum number of days allowed by the state law. Hospice patients need
opioids for pain relief from advanced illness and hospice practitioners need to be knowledgeable
of opioid regulations to abide by the law and to provide care without delay. Hospices need to
review opioid regulations and create policies for opioid use in inpatient and home-hospice
setting. A review of current opioid regulations and development of opioid prescription, use, and
disposal policies and practices will provide clarity to hospice and palliative care practitioners
engaged in care of EOL advanced cancer and non-cancer patients. These policies will guide the
hospice clinicians of their role and responsibility while caring for patients who are prescribed
opioids at EOL. This exercise will also advise hospice & palliative care practices to comply with
federal & state opioid regulations.
Theoretical Framework
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The Knowledge-to-Action (KTA) Process Framework (Figure 7) is a theoretical framework
in evidence-based implementation of knowledge into action. Graham et al. (2006) proposed the
KTA process conceptual framework to encourage use of research knowledge by a variety of
stakeholders in healthcare, from bedside clinician to boardroom executive. The KTA process has
two components: (1) knowledge creation and (2) action. Each component consists of several
phases on which the model continues to build. KTA is a dynamic and complex process, where

Figure 7. The Knowledge-to-Action Framework (KTA Framework). Reprinted from The
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Knowledge-to-Action Framework. Retrieved from https://medium.com/knowledgenudge/kt-101the-knowledge-to-action-framework-7fbe399723e8 October 2019
the framework knowledge creation process can be applied into action for long-term
sustainability. The two components have several sequential or simultaneous phases. These
phases are contained in a cyclic model to allow for a constant feedback loop.
The knowledge creation component consists of knowledge inquiry, knowledge synthesis,
and knowledge tools to tailor into creating knowledge for action. It is shaped as an inverted
funnel to gather several pieces of knowledge and filter the most applicable and refined
knowledge toward the action component. The knowledge built is moved into the next
component, action. Action has a series of phases that include adapting the knowledge,
implementing in the setting of choice, monitoring knowledge use and evaluating outcomes.
Barriers and facilitators to the implementation process are addressed within the action
component as well. Evaluating outcomes of the process during an action component helps
determine the impact of the knowledge gained on practitioner practices, patient care outcomes,
and the healthcare system. Graham et al. (2006) recommend creating a knowledge sustainability
plan that can withstand system changes.
Applicability:
The KTA Process Framework aligns with the scope and purpose of this project, which is to
synthesize accumulated opioid laws and regulation knowledge into actionable system-level
policy for hospice practice and evaluate consistent use of the policy by hospice care practitioners
(Figure 8). The cyclic process of the KTA framework places creators and users within a system
which is dynamic as well as adaptive. The policies created as a result of opioid regulation
synthesis will be adopted for use by hospice physicians, nurse practitioners, and nurses. The
policy will inform clinical practice protocol development. As the opioid regulations change, the
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policy and protocols will be modified and re-adopted. The policy built will be relevant,
applicable, and intuitive for hospice practitioners’ daily use. Potential barriers and facilitators to
policy implementation and adoption need to be considered before implementing the policy. To
help facilitate systemwide implementation, effective adoption, and continued compliance with
the policy, change champions need to be identified. The desired outcome of this project is
system-wide successful policy implementation and adoption.

Figure 8. The KTA Framework Applicability.
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Organizational Description & Analysis
Amedisys, Inc. is a for-profit healthcare at home company delivering personalized home
health, hospice and personal care, with the corporate office located in Baton Rouge, Louisiana,
and the executive office located in Nashville, Tennessee. Amedisys’ mission is to honor those we
serve with compassionate home health, hospice, and personal care services that apply the highest
quality clinical practices toward allowing our patients to maintain a sense of independence,
quality of life and dignity (About Amedisys, 2019). Amedisys provides in-home skilled nursing,
physical therapy, occupational therapy, speech language pathology, medical social work, home
aides, respiratory therapist, music therapist, life enhancement specialist, massage therapist and
hospice and bereavement services. Amedisys employs approximately 16,000 individuals at more
than 500 locations in more than 40 states, for providing home health, hospice and personal care
services.
Amedisys Inc. (Nasdaq: AMED) recently became the third-largest hospice provider in the
United States. Acquiring Compassionate Care Hospice in the year 2019 propelled Amedisys
companywide into the new markets of Michigan, South Dakota, Minnesota and Nebraska, while
also expanding its presence in Texas. Also, this acquisition allows Amedisys to offer a full
continuum of care in Florida. In addition, the company acquired RoseRock Healthcare in April
2019, Asana Hospice in January 2020, and Aseracare Hospice in June 2020. Amedisys’ postacquisition hospice operations include 190 care centers in 35 states with an average daily census
of about 12,000 patients. The idea is that by better managing beneficiary populations as they age
in place and reach the end of life, these integrated providers can help keep costs down and
quality high (Holly, 2018).
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Since Amedisys operates multi-site hospice practice in 35 states, a review of federal and each
state’s opioid rules corresponding to hospice practice was needed for Amedisys’ global
medication management policy. This DNP project developed an opioid rule database, crossreferencing federal and state opioid rules and corresponding hospice guidelines. Amedisys’
clinical services, operations, legal, and quality departments collaborated for this project. A
consult with external counsel was sought as needed. The project is timely and relevant to the
organization’s growing multi-state operations and the aims of the project are aligned with the
needs of the organization.
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CHAPTER 3
Methods
The goal of this project was to develop opioid use policy specifically for a multi-state
hospice practice and ensure Amedisys hospice care centers within 35 states adhere to the federal,
state, and local opioid regulations. This was accomplished by downloading federal, state, and
local opioid regulations and creating a repository. The downloaded regulations were appraised to
create policy themes including opioid prescription, opioid use, opioid disposal, and opioid
education. The regulations under those major policy themes were synthesized to create an opioid
policy for hospice practice. This policy was implemented system-wide, and an evaluation of
clinician’s successful adherence to the policy was conducted.
Goal: Review, synthesize and reconcile federal, state, and local opioid regulations and create a
system for a sustainable data base in order to develop and maintain opioid policies for
implementation in care centers across 35 states to ensure ongoing compliance with opioid laws
by a multistate provider.
Aim 1: Create a repository of federal, state, and local opioid regulations.
The assistant vice president of clinical regulatory (AVP Clinical Regulatory) was the project
lead who was responsible for analyzing the opioid regulations and develop the opioid policy
along with providing project oversight. The policy manager, who reports to AVP Clinical
Regulatory, downloaded the federal, state, and local opioid regulations. The opioid regulations
were searched using Google Chrome search engine with the following keywords - “opioid
regulations”, “opioid laws”, “opioid statutes”, and “opioid guidelines”. Additionally, state health
departments, state or local drug enforcement agencies, and federal Drug Enforcement Agency
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were searched for opioid regulations. The downloaded opioid regulations were deposited in a
Microsoft Office 365 SharePoint spreadsheet on the company’s intranet. The purpose of using
this software tool was to provide open access for employees for ease of collaboration on the
project. SharePoint software has the capability to alert the document owner every time an update
is made. The project lead accessed the SharePoint repository at a minimum once a week to
review newly added information, and extract opioid regulations related to opioid prescription,
required education for patients who are prescribed opioids, and medication disposal.
Evaluation/Analytic Plan: The policy manager was responsible for downloading the
opioid regulations several times a week. During weekly review, AVP Clinical Regulatory
ensured that new and/or updated opioid regulatory information has been added to the SharePoint
repository. The weekly review began after this DNP project proposal was approved by the Yale
school of nursing committee in Summer 2020.
Aim 2: Appraise and synthesize opioid regulations to develop a hospice practice specific
opioid policy.
The KTA Process Framework was utilized that aligned well with the scope and purpose of
this project. Under the framework, opioid laws and regulations were synthesized. The gathered
knowledge was transferred into actionable system-level policy for hospice practice. After
extracting the opioid regulations related to opioid prescription, required education for patients
who are prescribed opioids, and medication disposal for each state, the AVP Clinical Regulatory
conducted a comparative analysis of federal, state, and local regulations. The purpose of this
comparison was to identify similarities and differences among federal, state, and local
regulations. From the information extracted, the AVP Clinical Regulatory developed a draft
Opioid Management policy. An umbrella policy was developed for all those states among which
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there are no differences in opioid regulations (Appendix B). State specific opioid policy was
created for the states with variabilities in opioid regulations that cannot be reconciled with the
umbrella opioid policy due to different or additional mandates. The draft policies were sent for
review and comments to the key stakeholders in the interdisciplinary opioid project team. The
interdisciplinary opioid project team consisted of the hospice medical director, assistant vice
president of clinical regulatory, policy manager, internal counsel, operations manager, & clinical
manager. The review and comments were sought from the hospice medical director, internal
counsel, & clinical manager. Internal counsel provided guidance if an external counsel review
was needed. Once a month, the interdisciplinary opioid project team meeting met via phone
conference call. The purpose of this meeting was to address concerns, seek feedback, and
finalize policy. The recommendations from “Policy and Procedure Development Guidelines”
(Irving, 2014, para. 10) are listed under Appendix C and were used to develop the policy. The
policy was finalized by July 2020, and sent to hospice policy committee meeting for approval for
circulation. The hospice policy committee is a standing committee that meets monthly to approve
or reject requests for new policies, updated policies, and archiving policies.
Evaluation/Analytic Plan: Project lead accessed the SharePoint repository once a week
to review opioid regulations, and appraise them to create policy themes. The interdisciplinary
core team met once a month to assess the progress of & provide recommendations for opioid
policy content and theme development. These meetings were held monthly until August 2020,
then quarterly thereafter. The policy manager was responsible for sending timely meeting invites
and meeting minutes following the meeting. The stakeholders, consisting of senior operations
executives, were appraised monthly of the policy development.
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Aim 3: Implement the policy system-wide.
After policy committee approval in July 2020, the policy manager scheduled meetings with
a second team, the interdisciplinary implementation team. At this meeting, AVP Clinical
Regulatory shared the policy’s operational & documentation requirements with the
interdisciplinary implementation team. The interdisciplinary implementation team was
responsible for implementing the finalized policy system-wide, and consist of an operations
manager, a clinical manager, an education manager, & EMR clinical analyst.
The opioid policy requirements were to be embedded into operational processes and
electronic medical record (EMR) documentation software before system-wide policy
implementation & education can occur. Under AVP Clinical Regulatory oversight, the EMR
clinical analyst designed the policy updates to be embedded into the EMR software by first week
of August 2020. The opioid documentation in EMR software was designed for convenience of
data extraction to evaluate physicians, nurse practitioners, and nurses’ compliance with the
policy. The major EMR documentation categories listed were type of opioid prescription (long or
short acting), clinician communication with patient, non- pharmacological & alternative options,
patient education, opioid reconciliation, and opioid disposal. Appendix D contains a template of
the EMR documentation categories. The EMR clinical analyst was responsible for updating the
EMR operations manual including the policy and documentation updates.
Under AVP Clinical Regulatory oversight, the education manager designed policy education
to be disseminated to physicians, nurse practitioners, nurses, nurse managers, and care center
directors. This policy education included policy updates and EMR documentation specifications.
Prior to system-wide policy implementation, the AVP Clinical Regulatory pre-informed affected
personnel of the upcoming new policy. The mandatory Web-Ex policy education followed by an
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e-mail policy update blast was used for policy dissemination, in addition to clinical newsletter,
an online learning management system (self-education session), & onsite education sessions by
the care center director during a weekly staff meeting (Appendix E). The attendees had the
option to send their questions to a group email address at ~clinical.regulatory@Amedisys.com.
This email is delivered to the policy manager and AVP Clinical Regulatory.
The final Opioid Management policy was planned for system-wide implementation in the
third and fourth quarters of 2020. The system-wide dissemination & implementation was
planned for a 17 week period in three waves, at the 6 weeks, 7 weeks, and 4 weeks mark.
Evaluation/Analytic Plan: An attendance report was extracted from the web-ex and
learning management system, and the care center director was responsible for keeping
attendance for the on-site policy education sessions. The operations manager reported for
attendance compliance update to the core team after each mandatory Web-Ex policy education
session. The plan was to provide a one on one education by the care center administrator for
clinicians who were not able to attend the Web-Ex policy education. However, due to COVID-19
restrictions, those clinicians were assigned a self-learning course via online learning platform.
The care center administrator was responsible for keeping attendance for the mandatory Web-Ex
policy education sessions.
Aim 4: Develop a process to evaluate clinician’s adherence to the opioid policy.
To hardwire the new expectations, clinicians were encouraged and recognized for opioid
policy/protocol compliance. On the internal Yammer page, at standup morning meetings, or
during interdisciplinary meetings, a shout out was posted for clinician and/or a care center
staying compliant with opioid policy/protocol. Clinical leaders were encouraged to seek
feedback from clinicians at point of care about what’s working and what’s not, such as, ease of
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policy/protocol use, any hinderance, any feedback for protocol workflow improvement.
Additionally, the plan was for change champions (peer) and supervisors to seek feedback during
ride-along or competency check or staff luncheons, however due to COVID-19 restrictions, all
feedback was sought via phone.
Beginning September 2020, a weekly EMR report, for each care center, was produced &
reviewed by policy manager to assess compliance with policy implementation. The results were
shared with core team. The purpose of this report review was to assess percentage of clinician
compliance with the EMR documentation.
Evaluation/Analytic Plan: The goal was to achieve a 100% clinician compliance with
state and federal regulations. For the care centers falling behind the goal, the plan was to put
them on a two-part performance improvement plan. Part one was a root cause analysis (RCA) of
non-compliance to determine if it’s due to a system issue, a lack of understanding, or clinician
negligence. Based on the results of RCA, re-education of clinicians was to be conducted.
Pre- and post-policy implementation, a comparison review of opioid-related events was
conducted. The opioid-related events include prescriber failure to follow opioid prescription
protocol, clinician failure to follow opioid-related patient education policy, clinician failure to
follow opioid disposal protocol, and clinician failure to follow opioid medication reconciliation
during every home visit to the patient. A baseline was established using opioid-related events
during the calendar year 2019-2020. A robust goal was set of at least a 50% reduction in opioidrelated events at the end of first 2 weeks of training, at least 75% reduction after next 2 weeks of
training, and sustain at least 85% reduction after the next 4 weeks of training.
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Timeline
A visualization of the detailed project timeline for the actualization of this DNP project can
be found in Appendix F. Zoom, phone, or in-person meetings with DNP project advisor, Dr.
Marianne Davies began in October 2018, with discussions about project topic selection, and
continued with DNP project advisor, Professor Mary Ann Camilleri. The project proposal was
submitted in December 2019. To seek project proposal approval, a defense presentation was
scheduled in Summer of 2020 in front of the proposal approval committee of Yale School of
Nursing. The review of opioid regulations to draft the opioid policy began in Summer 2020.
A policy manager was hired in April 2019 to manage opioid regulation information
downloads and create the Sharepoint regulations repository. There was a total of two separate
teams working under this project - the Interdisciplinary Project team and Interdisciplinary Project
Implementation team. Both teams were created in Spring of 2020. The opioid policy was created
by mid-July 2020. Following policy creation, the implementation team began planning for policy
education, disseminations, & evaluation. The education and EMR documentation template build
was completed by end of July 2020. The policy implementation, including education &
dissemination of information was completed by end of Nov 2020. Attendance to policy
education sessions was tracked throughout the policy implementation phase. Beginning
September 2020, data from the EMR documentation compliance report was analyzed for
outcome evaluation. The proposed completion date of the project was December 2020. The
proposed date to have a manuscript submitted to a peer-reviewed journal or an abstract submitted
to a professional conference was by January 31, 2021. The abstract has been accepted for 46th
Biennial Convention (6-10 November 2021) of Sigma Theta Tau International Honor Society of
Nursing (Sigma).
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Leadership Immersion
Nursing education at the Doctorate of Nursing Practice level prepares the advanced practice
nurse (APN) to integrate evidence into practice and shape local and global views of nursing. This
DNP project allowed me to achieve my goals of working as a healthcare policy leader in the
hospice and palliative care setting, becoming involved in policy analysis, policy decisions, and
contributing to safe patient practices. Under the mentorship of end of life care and cancer
experts, and legal and risk management experts, I implemented the project, analyzed the results,
and made recommendations for practice and, if appropriate, future research.
The leadership immersion for this DNP project began in July 2020 and continued on to
Spring of 2021. The sponsor of this project was VP Clinical Risk. The hospice & palliative care
expert corroborating in the project was executive medical director and SVP Clinical Operations,
and legal expert corroborating in the project was VP Legal. The goals of leadership immersion
were engagement, collaboration, education, implementation and compliance. The
interdisciplinary project teams’ monthly meetings and ongoing email communications enabled
engagement with the organization’s clinical operations and education leaders. The
interdisciplinary project team meetings held to review opioid regulations for opioid policy draft
helped facilitate building knowledge through subject-matter expert feedback and understanding
policy impact on clinical operations and practice. Collaboration with the project implementation
team facilitated planning for system-wide policy dissemination and evaluating compliance
thereafter. The implementation team members included health information technology, training,
and clinical operations experts. A systematic dissemination and evaluation plan built with this
implementation team’s help provided consistent policy messages to the clinicians.

CREATING AN INTEGRATING POLICY

36

Chapter 4
Results
By end of November 2020, 100% of the hospice nurses, nurse practitioners and physicians
received education on umbrella opioid medication policy, and state specific guidance. The
system-wide dissemination & implementation was completed over a 4 week period in three
waves (Figures 9 & 10 ). At the end of 1st 2 weeks of policy implementation, 11 states in
northeast region had implementation completed. Likewise, at the end of next week, 15 additional
states in south, Midwest & southeast, and at the end of final week, 9 additional states in south &
west region had implementation completed. Due to social distancing restrictions uring COVID19 public health emergency, all policy education was provided remotely via Web-Ex or online
learning management platform.

Figure 9: Regions covered under policy dissemination waves schedule
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Policy Dissemination Schedule
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Figure 10: States completed by Wave schedule

Beginning December 1, 2020, the clinician compliance with opioid policy was monitored at
the end of every week. By end of first week of December 2020, through their documentation in
EMR, 100% of the clinicians in 28.5% (10 states) of all 35 states demonstrated 100%
compliance with state and federal regulations (Figure 11). Sharing this result via internal
Yammer page and highlighting states that had achieved compliance created a cadence of
demonstrated compliance in another 22 states. By the end of third week of December 2020,
100% of the clinicians in 91% (32 states) of all 35 states demonstrated 100% compliance with
state and federal regulations. These 32 states continued to maintain compliance with the umbrella
opioid medication policy, and state specific guidance for the rest of December 2020.
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Clinician Compliance Achieved
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Figure 11: Clinician compliance in 4 weeks

Only 40% clinicians in remaining 3 states achieved compliance by first week of January
2021. A root cause analysis was conducted to figure out the reason for non-compliance. A user
complacency to adopt documentation practices as dictated by the policy and a lack of supervision
by the immediate supervisor were found to be the root cause of non-compliance with the policy.
A re-education was provided to enforce policy compliance.
Pre- and post-policy implementation, a comparison review of opioid-related events was
conducted. In each of the opioid-related events category, at least 50% reduction was seen. In
opioid disposal category 66.66% and in medication reconciliation category 55.55% reduction
was seen (Table 1).
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# Pre-Policy

# Post-Policy

Implementation

Implementation

(Baseline)

(12/2020-1/2021)

(12/2019-1/2020)
Prescriber failure to follow opioid prescription
protocol

2

0

6

3

6

2

18

8

Clinician failure to follow opioid-related patient
education policy
Clinician failure to follow opioid disposal
protocol
Clinician failure to follow opioid medication
reconciliation during every home visit to the
patient

Table 1: A comparison review of opioid-related events

Discussion
This project was conducted at meso and macro levels in a multi-state multilevel organization.
Since the implementation of opioid policy was at a multi-state, multi-site organization, it was
important to take into account barriers and facilitators to the success of the implementation.
Barriers to policy implementation and adoption were activation of an emergency preparedness
plan causing operational disruption, a competing regulatory requirement, and a technology
breakdown. Due to COVID-19 public health emergency (PHE), the organizational resources
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were diverted causing a delay of 6 months from the original timeline. In September 2020, a new
hospice regulation about election of hospice benefit addendum was rolled out to be compliant
with Medicare mandate. This competing regulatory requirement caused significant delay in
opioid policy dissemination. The timeline was postponed to November 2020, and length of time
available to complete policy dissemination was shortened to one third of the original timeframe
of 17 weeks.
On the other hand, identifying change champions within the organization favorably enabled
and facilitated systemwide implementation, and effective adoption, and continued compliance
with the policy. The supervisors engaged in enforcing the policy guidance conducted continued
monitoring of clinician documentation in EMR, and provided real time correction. Although the
preparation was done to provide policy education via multiple modes, due to COVID19 PHE
social distance restrictions, in-person sessions were cancelled. All policy education sessions were
moved to broadcast style intranet platform or pre-recorded modules on company’s learning
management system. The education and operations teams were willing and quick to adapt to
mode of delivery and timeline changes.
A robust goal was set of at least a 50% reduction in opioid-related events at the end of first 2
weeks of training, at least 75% reduction after next 2 weeks of training, and sustain at least 85%
reduction after the next 4 weeks of training. A reduction of >50% was seen but couldn’t achieve
75% reduction goal in the observed timeframe. A longer length of observation period is needed
to see sustained compliance with opioid policy and sustained reduction in opioid-related events.
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Implications
“Large healthcare institutions may be the most complex in human history, and even small
healthcare organizations are barely manageable.” ~Peter Drucker
Increasingly, the care of advanced illness patients, palliative or hospice care, is being moved
to ambulatory settings. It is imperative that Quality and Safety initiatives are in place in the
ambulatory setting, in the same respect as those in place in acute care settings. It also imperative
that nursing healthcare policy leaders be prepared in policy analysis, change processes, business,
etc. to assure safe patient care. The implications of this DNP project are two-fold. First, this
project seeks is to assist hospice practices to meet regulatory compliance by making available the
most current legal and regulatory information to guide institutional policy and daily patient care
practices. In doing so, the risks associated with using outdated information, including
noncompliance with legal and regulatory requirements, will be mitigated. Second is to promote
patient safety by system-wide implementation of the policy. This will enable uniform
practitioner practice and reduce harm to the patient associated with variable practices within a
specific site location or region. If the company fails to comply with applicable laws and
regulations, it could be subjected to liabilities, including criminal penalties, civil penalties
(including the loss of our licenses to operate one or more of our businesses) and exclusion of a
facility from participation in the Medicare, Medicaid, and other federal and state health care
programs. If any of our facilities were to lose its accreditation or otherwise lose its certification
under the Medicare and Medicaid programs, the facility is at risk for loss of reimbursement from
the Medicare and Medicaid programs and other payors (Annual Reports, n.d.). Failure to comply
with opioid practice regulations could result in a disciplinary action against a prescriber or
clinician, including but not limited to probation, limitation, denial, fine, suspension, revocation
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or permanent revocation of the professional practice license (MSMS, 2018). Additionally, failure
to comply with opioid practice regulations may place patients at risk for medical error (Dy,
2016) or impair accessibility to opioids even when medically appropriate (Fehlberg, Broyles,
Wu, & Halpern, 2018).
This DNP project has applicability to further compliant opioid practice in a variety of care
settings nationwide. Especially in the current environment of large system, multistate practice, an
organization may be subject to similar or conflicting laws and regulations from state to state.
The framework developed in this project, an umbrella policy and identified tentacle policies with
state specific variation maintained through a centralized system, offers an efficient strategy for
multistate providers to ensure compliance. This system advances the quality of care by
prescribing providers. To further the uptake of this approach for broader impact, I plan to seek
publication in two nationally recognized journals, the Journal of Hospice & Palliative Nursing of
the Hospice & Palliative Nurses Association, and Journal for Healthcare Quality of the National
Association for Healthcare Quality. For dissemination to the hospice industry, I plan present at
the National Association for Home Care & Hospice and the National Hospice and Palliative Care
Organization conferences. In addition, I would like to explore with national nursing, hospice, and
patient safety organizations an opportunity to do a workshop, a teleconference, or a webinar.
Whether by synchronous or pre-recorded for asynchronous learning, this approach would further
expand the accessibility of this framework for compliant opioid practice.
Limitations
The presence of COVID-19 PHE created a heightened awareness for anticipating and
planning for failures or interruptions in the project before an adverse event occurs. Failure Mode
and Effects Analysis (FMEA) is a structured way to identify and address potential problems
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before they occur. If a FMEA was conducted before the project kicked off, resource allocation
disruption, deviation of resources, a backup training mode, etc. could have been anticipated and
planned for.
Conclusion
A review of current opioid regulations and development of opioid prescription, use, patient
education, and disposal policies and practices will provide clarity to hospice and palliative care
practitioners engaged in care of EOL advanced cancer and non-cancer patients. These policies
will guide the hospice clinicians of their role and responsibility while caring for patients who are
prescribed opioids at EOL.
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APPENDIX A
Evidence Table

Source

Issue
Related
to EBP

Design
Type*

Study
Design &
Study
Outcome
Measure(s)

Study
Setting &
Study
Population

Albert,
2017

Symptom
managem
ent at end
of life

Clinical
evidence

Evidence
synthesis

Palliative
medicine;
Persons at
the end of
life

Bernard,
2018

Pain
managem
ent and
opioid
epidemic

Clinical
evidence

Evidence
synthesis

Acute care
and primary
care
settings;
disabled
veterans,
cancer and
non-cancer
patients
with pain

Bonnie,
2017

Burden of
pain, pain
managem
ent,
opioid
epidemic,
&
alternativ
es to
opioids
for pain

Clinical,
legal, and
policy
evidence

Review of
scientific
literature to
support U.S.
Food and
Drug
Administrati
on (FDA)
regulatory
decision
making

Bibliograph
ic
databases,
federal,
state, and
local
agencies
and
organizatio
ns for
guidelines,

Study
Intervention
Review of
symptoms
experienced
by the
persons at
their end of
life, and
treatment
modalities
(medications
) to treat
those
symptoms.
Review of
use of
opioids for
pain
management
in the United
States;
Review of
role of
national
organizations
and pharma
companies in
promoting
opioid use
Review of
prescription
opioidrelated
harms;
Regulatory
Strategies to
Address
Prescription
Opioid-

Key Findings
Clinicians can
help patients
achieve comfort
at end of life and
death with
dignity by
effective
symptom control
through
medication.

Changing
political
landscapes
supported
escalation of
opioid epidemic;
Medical
community is
becoming
increasingly
aware of issues
related with
opioid use.
Incorporate
public health
considerations
into life-cycle of
opioid drug
development,
oversight, and
marketing,
including
regulatory
decisions.
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Study
Setting &
Study
Population

Study
Intervention

Key Findings

and
Related
LexisNexis Harms
database;
Pain
conditions,
Pharmacolo
gical &
nonpharmacolo
gical pain
managemen
t, policy &
cost of pain
treatment,
and impact
of opioid
epidemic on
public
health.
Population
with
chronic
pain

Bonnie,
2019

Role of
opioids in
managing
pain and
disparitie
s in
access to
pain
managem
ent

Peer
reviewed
commentary

Review of
scientific
literature,
federal
reports and
initiatives on
pain policy
and global
opioid
regulations
and access;
and expert
opinion.

Bibliograph
ic
databases,
FDA and
Institute of
medicine
(IOM)
reports,
Veterans
Administrat
ion and the
Department
of Defense
(VA/ DoD)
opioid
safety
initiative

Recommend
ation for
comprehensi
ve opioid
regulation
and pain
policy for
treatment
with opioids,
clinician
education,
and for
cultural
assimilation
of safe
opioid use
practices.

A
comprehensive,
population
health–level
strategy for pain
management
needs to be
aligned with the
opioid
regulations and
guidelines.
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Design
Type*

Study
Design &
Study
Outcome
Measure(s)
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Study
Setting &
Study
Population

Study
Intervention

Key Findings

report,
Centers for
Disease
Control and
Prevention
(CDC)
opioid
guidelines,
and United
States
opioid
regulatory
policy.

Brant,
2017

Breakthro
ugh
cancer
pain

Systematic
literature
review.

Population
with
chronic
pain
A search of
Forty-four
PubMed and studies
provide
CINAHL®
evidence
databases
for the use
was
of opioids
conducted
for the
using the
managemen
Putting
t
Evidence
Into Practice of breakthro
(PEP) search ugh cancer
procedure to pain - 6
systematic
identify
reviews/met
literature
a-analyses,
regarding
pharmacolog 25 studies,
ic strategies and 3
clinical
for
breakthroug guidelines
provide
h cancer
evidence
pain
for oral and
published
transmucos
from
al opioids;
January
2006 to June and 3

Adapting the
evidencebased
strategies
that are
recommende
d for treating
breakthrough
cancer pain
could
significantly
decrease
pain, and
quality of life
for patients
with cancer.

Opioids are the
mainstay of
management for
breakthrough
cancer pain,
however opioid
doses should be
individually
titrated.
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CDC,
2019

Issue
Related
to EBP

Opioid
overdose
and
opioid
prescripti
on for
chronic
pain
outside of
active
cancer
treatment,
palliative
care, and
end-oflife care.

Design
Type*

Guidelines

Study
Design &
Study
Outcome
Measure(s)

54

Study
Setting &
Study
Population

2016. These
studies were
then
synthesized
by the
Oncology
Nursing
Society
Putting
Evidence
Into Practice
pain team.

studies and
3 guidelines
provide
evidence to
give oral
opioids for
breakthroug
h cancer
pain

Access to
safer and
effective
chronic pain
treatment
while
reducing the
number of
people who
misuse or
overdose
from these
drugs.

Patientcentered
clinical
practices
for patients
with
chronic
pain who
are
prescribed
opioids to
manage
pain.

Study
Intervention

Three main
focus areas
when
prescribing
opioid for
managing
chronic pain:
Determining
when to
initiate or
continue
opioids for
chronic pain;
Opioid
selection,
dosage,
duration,
follow-up,
and
discontinuati
on;
Assessing
risk and
addressing
harms of
opioid use

Key Findings

Essential
discussion with
patients about:
Opioid
alternatives;
risks and
benefits of
opioid therapy;
ways to mitigate
patient risk;
treatment for
opioid use
disorder
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Study
Design &
Study
Outcome
Measure(s)

Study
Setting &
Study
Population

Cleary,
2015

Impact of Background
cancerInformation/E
related
xpert Opinion
pain, and
gaps in its
treatment

Use of
opioids for
pain control
in cancer
patients
experiencing
pain

Patients
diagnosed
with cancer
in acute &
palliative
care
settings

DeWeerd
t, 2019

United
States
opioid
epidemic

Article
synopses

Reasons for
opioid
epidemic in
the United
States
(U.S.), and
its spread to
other
countries.

Patients
with acute
or chronic
pain, in
cancer and
non-cancer
settings.

Dowell,
2016

Opioids
for
chronic
pain

Guidelines

Opioids for
chronic pain
recommenda
tions for
primary care
physicians

Chronic
pain outside
of active
cancer
treatment,
palliative
care, and
end-of-life
care;
Primary
care
practices

Study
Intervention

Key Findings

Cancer-pain
control
through
opioid use;
Palliative
care as a
means to
access to
opioids for
cancer pain
treatment in
low- &
middleincome
countries
Impact of
opioid
overuse on
U.S. healthcare system,
regulatory
regime,
culture and
socioeconomics.

Global efforts
for effective
cancer-pain
treatment
through
“cornerstone
trinity,” are
medication
availability
(including cost
control),
education, and
policy reform.

Recommend
ations for
primary care
physicians
about when
to initiate or
continue
opioids for
chronic pain;
opioid
selection,
dosage,
duration,
follow-up,

•

A tight drug
regulatory
system is
essential for
evaluating the
safety and
effectiveness of
drugs when used
as directed. This
can prevent the
potential opioid
misuse.
Nonpharmac
ologic
therapy and
nonopioid
pharmacolo
gic therapy
are preferred
for chronic
pain. If
opioids are
used, they
should be
combined
with
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Design &
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Measure(s)
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Study
Setting &
Study
Population

Study
Intervention
and
discontinuati
on; and
assessing risk
and
addressing
harms of
opioid use.

Duthey,
2014

Access to
opioid
analgesic
s

Comparative
analysis

Comparing
the actual
consumption
of opioid
analgesics
with the
calculated
need for
countries
and World
Health
Organization
regions in
2010 as
compared
with 2006.

Adequacy
of
consumptio
n of opioid
analgesics
in countries
around the
world in
patients
with
moderate
and severe
pain.

Calculate the
morbiditycorrected
needs per
capita for
opioid
analgesics
and the
consumption
for the top 20
Human
Development
Index
countries.
Calculate the
number of
people living
in countries

Key Findings

•

nonpharmac
ologic
therapy and
nonopioid
pharmacolo
gic therapy,
as
appropriate.
medicationassisted
treatment
with
buprenorphi
ne or
methadone
in
combination
with
behavioral
therapies)
for patients
with opioid
use disorder.

The
consumption of
opioid
analgesics
remains
inadequate in
most of the
world: 66% of
the world
population has
virtually no
consumption,
10% very low,
3% low, 4%
moderate, and
only 7.5%
adequate.
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Study
Setting &
Study
Population

Study
Intervention

Key Findings

at various
levels of
adequacy.
Dy, 2016

Patient
Critical
safety and appraisal
end-oflife care

Synthesis of
systematic
reviews and
additional
research on
improving
patient
safety and
end-of-life
care.

Palliative
and end-oflife care

Compare
Patient safety
and end-oflife care’s
perspective
on common
issues in
traditional
patient safety
frameworks;
Current
approaches
in each field
can inform
the other;
Patient safety
at end-of-life
comparison
to patient
preferences
for lifesustaining
treatment.

Understanding
the comparable
issues between
patient safety
and end-of-life
care and their
different
perspectives, can
benefit both
fields learn and
improve patient
care in palliative
and end-of-life
care.

Fehlberg,
2018

Opioid
crisis and
end-oflife care

Reactions to
opioid crisis
and impact
on patients
during their
end-of-life
with the
appropriaten
ess of their
opioid
prescriptions
.

Palliative
and hospice
care
patients
experiencin
g pain at
end-of-life.

Recent
regulatory
updates
impacting
access to
pain
management
in palliative
and hospice
care patients.

Education and
training for
palliative care
and hospice
providers
regarding
appropriateness
of opioid
analgesics.

Policy review
and synopses
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Issue
Related
to EBP

Design
Type*

Study
Design &
Study
Outcome
Measure(s)

58

Study
Setting &
Study
Population

Study
Intervention

Key Findings

Gabbard,
2018

Substance Peer
use
reviewed
disorder
commentary
(SUD)
and
hospice
care

Case review
of SUD
patient to
develop
understandin
g on how to
deal with
patients who
have SUDs
and
uncontrolled
pain.

Terminally
ill cancer
patient in an
inpatient
care setting.

Screening of
patients with
SUD, review
of current
guidelines,
and treatment
approaches
for hospice
patients in
pain who
have SUD.

Screen All
Patients for
SUDs; Complete
a
Comprehensive
Pain, Opioid,
and Social
History in All
Patients; Adapt
Practices from
SUD Treatment
Programs to
Hospice Patients
with Active
SUD;
Communicate
with Patients
Identified to be
Misusing
Opiates;
Increase
Education of
SUDs for
Hospice
Providers.

Garcia,
2013

Chronic
pain,
opioid
abuse,
and
policy

Review of
scientific
literature,
federal
reports and
state
regulations,
and
initiatives on
pain policy
for opioid
regulations
and access.

Problem of
chronic
pain and
prescription
painkiller
abuse and
overdose in
public
health

Inadequate
treatment of
pain in the
U.S. and the
subsequent
rise of
prescription
painkiller
abuse,
misuse, and
overdoses;
Actions
taken by
states to
regulate the
prescribing

It is important to
evaluate the
impact opioid
prescription
policies are
having, both in
reducing
painkiller abuse,
misuse, and
overdoses and
on legitimate
access to pain
care.

Policy review
and analysis
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Source

Issue
Related
to EBP

Design
Type*

Study
Design &
Study
Outcome
Measure(s)

59

Study
Setting &
Study
Population

Study
Intervention

Key Findings

of controlled
substances.
Hahn,
2018

Opioid
epidemic
and
opioid
policy

Expert
commentary

Review and
analysis of
federal
policies and
funding to
combat
opioid crisis
in the U.S.

U.S.
communitie
s impacted
by
overprescri
bing of
opioids and
the illegally
produced
heroin.

Align
healthcare
pain
protocols to
federal
opioid
policies,
federal
funding and
programs;
opioid
addiction
prevention,
opioid
addiction
treatment,
overdose,
reversal, and
recovery.

Presidential
Opioid Crisis
Plan needs
sustained
funding to
impact
communities
that have been
hit hard by the
opioid epidemic.
Nurses to
advocate for
Congress to
address the
recommendation
s of the
Presidential
Commission
Report about
opioid crisis,
training of lay
people and first
responders to
administer
naloxone, and
increasing
access to
treatment for our
patients.

Harm
reduction
coalition,
n.d.

Opioid
overdose
preventio
n

Report
analysis and
advocacy

Review of
opioid
overdose
CDC report
and
advocacy to

Prescription
and nonprescription
drug
overdose

Educating
drug users
about
overdose
recognition
and response

Drug overdose
deaths can be
contributed to
prescription and
non-prescription
drugs; drug
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Source

Issue
Related
to EBP

Design
Type*

Study
Design &
Study
Outcome
Measure(s)
prevent
overdose
deaths.

Federal
policy
declaration

60

Study
Setting &
Study
Population
deaths in
the U.S.

Key Findings

can prevent
overdose
deaths and
reduce harm.
Naloxone is
a safe
antidote for
opioid
overdose.
Opioid crisis•
is a public
health
emergency
and a top
priority of
the federal
government.

overdose can be
prevented.

HHS,
2017

Opioid
crisis

Howell,
2017

Prescripti Policy review
on Drug
and advocacy
Monitorin
g
Program
(PDMP)

Review of
Missouri
(MO) state
opioid laws
related to
PDMP.

PDMP bills
in the state
legislature

Passing state
bills to
establish the
PDMPs in
the state of
MO.

PDMP bill in the
MO state
legislature is still
pending. There
have been local
efforts however
to establish
county-based
PDMPs
throughout the
state.

IASP,
2017

Pain
terminolo
gy

Alphabetical
ly arranges
listing of
pain related
words

IASP Task
Force on
Taxonomy

A Current
List of 35
pain terms
with
definitions
and notes on
usage

Pain
terminology
definitions are
updated on a
periodic and
continual basis
by IASP's pain
experts.

Terminology
listing

Addressing
Opioid
the
crisis in the
nationwide
U.S.
opioid
public health
emergency

Study
Intervention

Improve access
to prevention,
treatment, and
recovery support
services; and
target the
availability and
distribution of
overdosereversing drugs
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Study
Design &
Study
Outcome
Measure(s)

61

Study
Setting &
Study
Population

Source

Issue
Related
to EBP

Johnson,
2018

Opioid
crisis

Case study

Interviews
with public
officials
about
county’s
opioid
policies.

Suburban
Northern
Kentucky’s
three
counties
facing
opioid
crisis.

The public
officials were
asked
questions
regarding
specific
policies in
their
counties,
their
opinions on
the causes of
the opioid
crisis, their
assessment
of the
regional
opioid crisis,
and their
views on the
efforts of a
variety of
actors,
including the
city, state,
and federal
governments,
the public,
and civic
organizations
.

All three
counties are
addressing the
problem using
several tactics,
including
prevention,
treatment, law
enforcement,
and long- term
healthcare.

Katz,
2017

Cancer
related
breakthro
ugh pain
(BTcP)

Data analysis

A crosssectional
observationa
l
survey data
analysis for
a subset of
patients with
BTcP.

Community
-dwelling
adults with
cancer and
chronic
pain.

For patients
with cancer
pain also
experiencing
breakthrough
pain were
surveyed for
pain triggers,
pain onset,
and average

BTcP among
communitydwelling
patients with
cancer continues
to be a health
burden and
reveals
opportunities for
improvement.

Design
Type*

Study
Intervention

Key Findings
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Source

Issue
Related
to EBP

Design
Type*

Study
Design &
Study
Outcome
Measure(s)

62

Study
Setting &
Study
Population

Study
Intervention

Key Findings

and worst
pain intensity
during the
preceding 24
hours,
respectively,
and high
interference
with activity,
mood, ability
to walk and
work, social
relations,
sleep, and
enjoyment of
life.
McCullo
ugh,
2018

Substance Policy
use
analysis
disorder
(SUD)
treatment

A review of
Congression
al opioid
legislation
for
substance
use disorder
(SUD)
treatment

SUD
persons
requiring
treatment
coverage
under state
Medicaid
programs

The
SUPPORT
for Patients
and
Communities
Act
reauthorizes
funding for
state
Medicaid
programs for
medicationassisted
treatment
(MAT) for
opioid
addiction and
other SUD.

Although the
MAT funding
for SUD is a
step in the right
direction, longterm funding is
needed to end
the opioid crisis
and sustain the
results.

Mcginty,
2018

High-risk
opioid
prescribin
g
practices

A primary
quantitative
analysis to
estimate the
effects of the
opioid laws

U.S. states
that have
enacted at
least one of
the multiple
types of

To
characterize
the
implementati
on and
enforcement

The opioid
epidemic is
driven by high
rates of opioid
prescribing by

Mixedmethods
study
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Source

Issue
Related
to EBP

Design
Type*

Study
Design &
Study
Outcome
Measure(s)
enacted in
states
comparing
to control
pool states.
The
overarching
goals of the
study are on
two primary
sets of
outcomes:
(1) high-risk
opioid prescribing
patterns and
(2) treatment
of chronic
non- cancer
pain.

Meldrum
, 2016

Opioid
epidemic

Expert
commentary

Historical
context of
opioid
prescription
epidemic
and resulting
impact

63

Study
Setting &
Study
Population

Study
Intervention

Key Findings

laws
designed to
curb highrisk opioid
prescribing
practices
associated
with opioid
misuse,
dependence
, and
mortality,
including
high-dose
opioid
prescribing,
long-term
opioid
prescribing
for acute
pain, and
overlapping
opioid and
benzodiaze
pine
prescription
s.

of the four
types of
state laws to
curb highrisk opioid
prescribing
practices and
to evaluate
the
independent
effects of
those laws,
accounting
for variation
in
implementati
on and
enforcement
across states.

healthcare
providers;

Patients
with
chronic
pain who
are
prescribed
opioids to
treat pain in
last 3
decades.

Exploring the
campaign for
the long-term
use of
opioids in
chronic (&
non-cancer)
patients.

Alternative
treatment
modalities to
opioid
medications are
needed.
Strict physician
supervision is
needed when
opioids are
prescribed for
chronic pain.

Impact
evaluation of
implementation,
enforcement,
and outcomes of
policies
designed to curb
high-risk opioid
prescribing
practices is
needed;
Inform the
dynamic policy
environment to
pass, revise,
implement, and
enforce varied
laws to address
opioid
prescribing each
year.
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Source

Issue
Related
to EBP

Design
Type*

Study
Design &
Study
Outcome
Measure(s)

64

Study
Setting &
Study
Population

MSMS,
2018

Opioid
epidemic
and law

Policy
analysis

A review of
Michigan
state opioid
laws

Michigan
state opioid
laws for
licensed
prescribers
of opioid
medications
to adults
and minors.

National
Cancer
Institute,
n.d.

Cancer
terminolo
gy

Terminology
listing

Alphabetica
lly
arranged
dictionary
of cancer
terms

National
cancer
institute
dictionaries

NCSL,
2019

Opioid
overdose
epidemic
and laws

Policy review

A review of
U.S. state
opioid laws

Misuse of
prescription
and illicit
opioids in

Study
Intervention

Key Findings

Effective
June 1, 2018,
Michigan
state opioid
laws
regarding
informed
consent
before
prescribing
opioid
medications,
automated
prescription
system
checks,
limitation on
prescribing,
patientprescriber
relationship,
SUD, and
MAT.
A Current
List of
8,680 terms
related to
cancer and
medicine.

Failure to
comply with the
Michigan state
opioid laws
could result in
the disciplinary
actions against a
physician’s
license. Noncompliance
could result in
disciplinary
action by the
Michigan Board
of Medicine.

CDC
guidelines
and laws
related to

States have
enacted laws to
tackle
prescription

A dictionary of
cancer and
biomedical
terms defined in
non-technical
language. Terms
and definitions
are reviewed by
a
multidisciplinary
panel of
reviewers and
new terms are
added each
month.
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Source

National
Science
and
Technolo
gy
Council,
2018

Issue
Related
to EBP

National
opioid
crisis

Design
Type*

Federal
committee
report

Study
Design &
Study
Outcome
Measure(s)

Federal
roadmap for
research &
development
(R&D) to
curb the
national
opioid crisis
in the U.S.

65

Study
Setting &
Study
Population

Study
Intervention

Key Findings

the
community

opioid
prescription
regulation,
prescription
drug
monitoring
programs,
access to
naloxone,
pain clinic
regulation,
provider
education
and training.

drug misuse ,
addiction and
overdose
through the laws
related to
prescription
drug monitoring
programs, access
to naloxone,
pain clinic
regulation,
provider
education and
training

U.S.
communitie
s impacted
by opioid
public
health
emergency.

Federal
opioid fast
track action
committee
(FTAC)
organized its
efforts in a
Roadmap,
and
identified
seven areas
of R&D: (1)
the Biology
and
Chemistry of
Opioid
Addiction
and Pain; (2)
NonBiological
Contributors
to Opioid
Addiction;
(3) Pain
Management
; (4)
Prevention of
Opioid

For long-term
resolution of the
opioid crisis, the
federal
departments and
agencies doing
substantial
research efforts
related to the
opioid crisis
need to
strategically
coordinate those
efforts. This step
is critical to
ensure that the
Administration
delivers the
comprehensive
science response
that the opioid
crisis demands.
.
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Source

Issue
Related
to EBP

Design
Type*

Study
Design &
Study
Outcome
Measure(s)

66

Study
Setting &
Study
Population

Study
Intervention

Key Findings

Addiction;
(5)
Treatment of
Opioid
Addiction
and
Withdrawal;
(6) Overdose
Prevention
and
Recovery;
and (7)
Community
Consequence
s of Opioid
Addiction.

National
Science
and
Technolo
gy
Council,
2019

National
opioid
crisis

Federal
committee
report

Federal
roadmap for
research &
development
(R&D) to
curb the
national
opioid crisis
in the U.S.

U.S.
communitie
s impacted
by opioid
public
health
emergency.

The research
recommendat
ions
generated by
the FTAC in
each of these
areas, as well
as an eighth
section that
includes
recommendat
ions on ways
to enhance
coordination,
are
summarized
in this report.
Based on the
feedback
from general
public and
healthcare
community
in November
2018,
Federal

For long-term
resolution of the
opioid crisis, the
federal
departments and
agencies doing
substantial
research efforts
related to the
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Source

Issue
Related
to EBP

Design
Type*

Study
Design &
Study
Outcome
Measure(s)

67

Study
Setting &
Study
Population

Study
Intervention
opioid fast
track action
committee
(FTAC)
organized a
revision to its
efforts in a
Roadmap,
and
identified
seven areas
of R&D: (1)
the Biology
and
Chemistry of
Opioid
Addiction
and Pain; (2)
NonBiological
Contributors
to Opioid
Addiction;
(3) Pain
Management
; (4)
Prevention of
Opioid
Addiction;
(5)
Treatment of
Opioid
Addiction
and
Withdrawal;
(6) Overdose
Prevention
and
Recovery;
and (7)
Community
Consequence

Key Findings
opioid crisis
need to
strategically
coordinate those
efforts. This step
is critical to
ensure that the
Administration
delivers the
comprehensive
science response
that the opioid
crisis demands.
FTAC provided
a forum for
federal
interagency
discussions that
may lead to
closer
coordination of
strategy and
activities.

.
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Source

Issue
Related
to EBP

Design
Type*

Study
Design &
Study
Outcome
Measure(s)

68

Study
Setting &
Study
Population

Study
Intervention

Key Findings

s of Opioid
Addiction.

Painter,
2017

Opioid
crisis and
healthcar
e reform

Policy
analysis

A review of
opioid
policy,
current
healthcare
reform and
its impact on
opioid crisis,
and
consideratio
ns for nurse
on the
frontlines.

Nurses who
provide
assessment
for patients
with opioid
use
histories;
Affordable
care act
(ACA) and
federal,
state, and
local opioid
policy
changes.

The research
recommendat
ions
generated by
the FTAC in
each of these
areas, as well
as an eighth
section that
includes
recommendat
ions on ways
to enhance
coordination,
are
summarized
in this report.
Local policy
about
availability
of naloxone
to prevent
opioid
overdose
deaths;
Provision of
MAT for
individuals
with SUD
who have
health
insurance
under ACA;
Nurses’
involvement
in
community
based opioid
overdose
prevention’

Need for
continued
resources to
combat the
ongoing
epidemic, and
sustain
prevention
efforts; Nurses
as healthcare
leaders to break
the stigma of
opioid addiction,
and support
vulnerable
populations
through
Interprofessional
collaboration for
treatment,
education, and
advocacy.
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Source

Issue
Related
to EBP

Design
Type*

Study
Design &
Study
Outcome
Measure(s)

69

Study
Setting &
Study
Population

Parker,
2018

Opioid
epidemic

Policy review
and advocacy

Most
common
state policy
responses
and review
to better
understand
the most
prevalent
state
responses to
the opioid
crisis.

U.S.
communitie
s impacted
by opioid
public
health
emergency.

Prescripti
on drug
abuse
policy
system,
2019

Opioid
overdose

Policy
analysis

A review of
Good
Samaritan
overdose
prevention
laws.

Opioid
overdose
bystanders
in the U.S.
communitie
s.

Study
Intervention
education,
and advocacy
programs.
Six primary
approaches
states have
taken to
combat the
opioid
epidemic:
opioid
prescribing
policies,
opioid
education in
the
communities,
MAT for
SUD,
overdose
prevention,
disciplinary
actions and
penalties.

States have
enacted
"Good
Samaritan"
laws that
create
immunities
or other legal
or broad
protections
for people
who call for
help in the
event of a
drug
overdose.

Key Findings

An evaluation of
state approaches
to combat opioid
crisis is needed,
to understand
the impact of
policy
effectiveness,
funding
resources and
sustainability of
the efforts.

By enacting
Good Samaritan
laws, states are
making an effort
to prevent opioid
overdose deaths,
and reduce
stigma
associated with
treatment for
SUD.
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Study
Design &
Study
Outcome
Measure(s)

70

Study
Setting &
Study
Population

Issue
Related
to EBP

Design
Type*

Prescripti
on drug
abuse
policy
system,
2019

Opioid
overdose

Policy
analysis

A review of
opioid
overdose
prevention
laws.

Opioid
overdose
deaths in
the U.S.
communitie
s.

Administerin
g naloxone
hydrochlorid
e
(“naloxone”)
can reverse
an opioid
overdose and
prevent the
unintentional
deaths.

Prescripti
on drug
abuse
policy
system,
2019

Opioid
overdose
deaths

Policy
analysis

A review of
pain
management
clinic laws.

Opioid
overdose
deaths in
the U.S.
communitie
s.

Prescriptions
for opioids
are involved
in almost
half of all
opioid
overdose
deaths; state
laws regulate
pain
management
clinics, clinic
owners, and
the
physicians
that work at
the clinics.

Prescripti
on drug
abuse
policy
system,
2019

Opioid
misuse
and
overdose
deaths

Policy
analysis

A review of
opioid
prescribing
practice
laws.

Opioid
misuse and
overdose
deaths in
the U.S.
communitie
s.

Prescription
drug
monitoring
programs
(PDMPs)
collect
patientspecific
prescription
information
in centralized
databases.

Source

Study
Intervention

Key Findings
By enacting
naloxone laws,
states are
making an effort
to prevent opioid
overdose deaths
by making
naloxone easily
and readily
available in the
common
household.
By enacting pain
management
clinic laws,
states designate
certain medical
practices that
provide
management
services as pain
management
clinics and
subject these
clinics to extra
regulation.

By funding
PDMPs, states
continue to
commit to
reduce the
misuse of
controlled
medicines.
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Source

Issue
Related
to EBP

Design
Type*

Study
Design &
Study
Outcome
Measure(s)

71

Study
Setting &
Study
Population

Study
Intervention

Key Findings

S.2680,
115th
Congress
, 2018

Opioid
public
health
emergenc
y

Policy
analysis

Federal bill
to address
the national
opioid crisis.

Opioid
misuse and
overdose
deaths in
the U.S.
communitie
s.

Opioid Crisis
Response
Act of 2018,
S. 2680
includes laws
for pain
research;
controlled
substance
safety;
treatment and
recovery
from opioid
overdose,
misuse, and
SUD; impact
of opioid
crisis on
workforce
and
economy;
overdose
prevention;
and
education.

By enacting
federal opioid
laws, states are
making an effort
to prevent opioid
overdose deaths.

SAMHS
A, 2017

Opioid
overdose
deaths

Policy review
and advocacy

A review of
Good
Samaritan
overdose
prevention
federal laws
and state
policies.

Opioid
overdose
bystanders
in the U.S.
communitie
s.

Overdose
Good
Samaritan
laws provide
legal
protections
for
individuals
who call for
emergency
assistance in
the event of a
drug
overdose.
However,
lack of
awareness

Raising
awareness by
educating the
prescribers,
healthcare
workers, law
enforcement
personnel,
criminal justice
personnel,
prescription and
non-prescription
drug users, and
the general
public about the
state’s Overdose
Good Samaritan
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Source

Issue
Related
to EBP

Design
Type*

Study
Design &
Study
Outcome
Measure(s)

72

Study
Setting &
Study
Population

Study
Intervention
and
understandin
g of these
laws may be
limiting their
effectiveness
in the
community
and
preventing
the criminal
justice
system from
fully
observing
them.

SAMHS
A, 2018

Opioid
overdose
public
health
emergenc
y

Toolkit

A review of
opioid use
disorder
facts,
guidelines,
opioid laws,
and
resources for
opioid use
disorder
survivors.

Persons
who have
opioid use
disorder,
their
families,
and the
practitioner
s treating
opioid use
disorders.

For drug
users, their
families, and
prescribers,
the toolkit
describes:

Key Findings
law
requirements
and limitations,
will help full
actualization of
the law.

The opioid
overdose
survivors need
the support of
family, friends,
prescribers, and
community
• strategies to resources to
recover and
prevent
sustain the
overdose
results.
deaths,
• essential
steps for
first
responders,
• medical,
billing, and
legal
considerati
ons for
prescribers,
• safety
advice, and
• resources
and
available
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Source
Saunders
, 2018

Issue
Related
to EBP
Opioid
use
disorder

Design
Type*
Systematic
review

Study
Design &
Study
Outcome
Measure(s)
A review of
published
and grey
literature to
identify
federal and
state policy
strategies
regarding
opioid
misuse
among
pregnant
women.

73

Study
Setting &
Study
Population
Opioid
misuse
during
pregnancy
and
treatment of
opioid use
disorder
around the
time of
childbirth.

Study
Intervention
support
networks
Current
federal and
state laws
that impact
women
before
pregnancy,
during
pregnancy, at
birth, and
postpartum
were
reviewed to
identify gaps
and
challenges
related to
treatment
efforts of
opioid use
disorder.

Key Findings
Gaps were
identified in
current policies there’s limited
attention to
prevention of
opioid misuse
among
reproductive-age
women, and
there’s a lack of
policies
addressing
opioid misuse
among
postpartum
women. There
do exist access
to care barriers
for women who
misuse opioids,
including
provider
shortages, lack
of resources,
stigma, and fear
of legal
consequences.
It is imperative
that
policymakers
address the
opioid epidemic,
the unique needs
of pregnant and
postpartum
women and
barriers to
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Source

Issue
Related
to EBP

Design
Type*

Study
Design &
Study
Outcome
Measure(s)

74

Study
Setting &
Study
Population

Study
Intervention

Key Findings
treatment should
be addressed.

Scholten,
2019

Access to
opioid
analgesic
s

Meta-analysis

Tompkin
s, 2017

Chronic
pain

Evidence
synthesis

Statistics for
18
controlled
opioid
medicines
that are
primarily
used as
analgesics
was used for
the study.
Quantitative
methods
were used to
summarize
the results
using
Adequacy of
Opioid
Consumptio
n (AOC)
Index.
Critical
appraisal,
evaluation
and
synthesis of
medical
literature,
research
studies and
articles
regarding
pain
treatment
and pain
regulations.

Internationa
l Narcotics
Control
Board’s
Opioid
consumptio
n statistics
database
from 1990
to 2015
were used
for this
research
project,
containing
the annual
consumptio
n by
country and
by
substance.

Monitoring
adequacy of
opioid
consumption
is important
to identify
countries that
have
insufficient
access to
adequate
pain
management.

Access to opioid
analgesic
consumption
continues to be
inadequate in
many countries
around the world
and
improvement of
adequacy is
limited to a
number of
countries and
that policy
efforts do not
manage to keep
pace with the
increasing world
population.

Chronic
pain in
Americans
and need
for pain
treatment

Narrative
about chronic
pain, its
pharmacolog
ic (opioid
and nonopioid
analgesics)
and
alternative
treatment,
and
healthcare
practitioner
chronic pain
management
practice

To manage
chronic pain,
non-opioid
medications, and
nonpharmacologic
treatment
modalities need
to be explored,
including safety
and efficacy of
the alternative
treatments and ,
needs and
barriers to
utilization of
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Source

Issue
Related
to EBP

Design
Type*

Study
Design &
Study
Outcome
Measure(s)

75

Study
Setting &
Study
Population

Study
Intervention
consideration
s.
Missouri has
not been able
to pass
PDMP
legislation in
last 7 years.

Weber,
2019

Opioid
monitorin
g

Policy review
and advocacy

A review
current state
of
Missouri’s
prescription
drug
monitoring
program
(PDMP)
legislature.

Patient
advocates,
politicians,
experts and
members of
the medical
community
of the state
of Missouri.

WHO,
2018

Cancer
pain

Guidelines

Evidencebased
guidance on
utilization of
pharmacolog
ical and
radiotherape
utic
management
for cancer
pain.

Cancer pain
in
adolescents,
adults, and
older adults.

Provide pain
management
guidance to
healthcare
providers for
relief of
cancer pain.
Provide
policy
guidance for
opioids and
prescribing
regulations
for effective
and safe
cancer pain
management.

WHO,
2019

Essential
medicines
and
health
products

Current
listing and
databases of
essential
medicines

Chronologic
ally
arranged
essential

The WHO
Model Lists
of Essential
Medicines f
or adults

The list is
developed
based on
recommendat
ions made by

Key Findings
non-opioid
therapies.
Missouri state
republican
conservative
caucus has
filibustered the
passing of
PDMP
legislation in
state senate.
Medical and
pharmacy
communities
have voluntarily
opted for PDMP
in Missouri’s 72
jurisdictions
covering 84% of
the population.
For safer cancer
care and for
improving
quality of life of
cancer patients
experiencing
pain, cancer pain
management
should be a part
of cancer care
treatment plan.

The WHO
Model Lists of
Essential
Medicines has
been updated
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Source

WHO,
2019

Issue
Related
to EBP

Essential
medicines
and
health
products

Design
Type*

Current
listing of
essential
medicines

Study
Design &
Study
Outcome
Measure(s)
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Study
Setting &
Study
Population

Study
Intervention

Key Findings

medications
lists

and
children,
from the
year 2002
to current.

the WHO
Expert
Committee
on the
Selection and
Use of
Essential
Medicines
for the
Essential
Medicines
Lists update,
including a
database of
antibiotics.

every two years
since 1977.
There are
separate lists of
essential
medications for
adults and
children.

Alphabetical
ly arranges
listing of
essential
medications

The 2019
WHO
Model Lists
of Essential
Medicines f
or adults
and
children.

The list is
developed
based on
recommendat
ions made by
the WHO
Expert
Committee
on the
Selection and
Use of
Essential
Medicines
for the
Essential
Medicines
Lists update.

The core list
presents a list of
medicine needs
for a basic
health-care
system, listing
the most
efficacious, safe
and cost–
effective
medicines for
priority
conditions.
The
complementary
list presents
essential
medicines for
priority diseases,
for which
specialized
diagnostic
and/or specialist
care is needed.
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Aim 2: Development of opioid policy and clinical documentation protocol
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APPENDIX C
Policy and Procedure Development Guidelines
(Reprinted from Policies and Procedures for Healthcare Organizations: A Risk Management
Perspective. Retrieved from https://www.psqh.com/analysis/policies-and-procedures-forhealthcare-organizations-a-risk-management-perspective/ December 2019)
Recommendation

Rationale

Define all terms used within the policy.

It is useful to put these definitions at the beginning
of the policy. If terms are not defined, they may be
misconstrued by staff and/or when later scrutinized
by plaintiff lawyers.

Refrain from using superlative words or statements,
such as:
The presence of superlative adjectives is sometimes
alleged by plaintiff lawyers to be a “guarantee” of a
certain outcome.
a) Highest, safest, best (level of care)
b) Assure, ensure (preferable to use “to promote”)
Exercise caution when using absolutes such as
Many circumstances allow for clinical judgment.
shall, must, or do not unless intended as such.
Naming a policy “Chain of Command Policy” is
preferable to naming it, “Disagreement over patient
Select a simple, recognizable name for the policy.
care.” Staff will have an easier time locating a policy
with a familiar name.
Combine separate policies on the same subject into For instance, the policy for medical screening
one policy. If it becomes lengthy, create a table of examinations, transfer in/out, reporting EMTALA
contents so the user can easily locate specific
violations, etc. should appear in a single EMTALA
sections.
policy.
Passive voice: “The specimen container should be
labeled.”
Use the active rather than the passive voice when
writing specific procedure action steps.
Active voice: “Place a label on the specimen
container.”
Ensure responsibility for carrying out each action
Each section should have two columns: the one on
step is explicitly stated, not implied.
the left outlines the action to be taken, and the one
on the right says who is responsible for carrying out
each step.
Obtain the sign-off of all stakeholders (domain
It is not uncommon to see “nursing” policies that
leaders) affected by each policy, as well as each
outline actions an independently credentialed
oversight committee or entity that reviewed and
physician is expected to take. Any policy that
approved of it (e.g.. Medical Executive Committee outlines medical staff responsibilities warrants their
[MEC]).
input during development and subsequent reviews.
Medical staff members also need to know where to
access those policies.
Require each approving entity or person to sign off Cover sheets for sign off are not effective for
on each individual policy. In years past, paper policy electronic documents.
manuals often included a “cover sheet” as a sign-off
page, which showed the date of approval and
signature of the approving leader, in lieu of him/her
signing each policy.
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Recommendation
Note the date of origin of the policy and each
subsequent review or modification date within the
body of the policy, typically on the last page near the
sign-offs:
Date of origin: ____
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Rationale

Pay particular attention to how the approvals for
subsequent policy updates are documented in the
electronic version of the policy.

Review date: ____
Review date: ____
Establish naming and numbering conventions for
use across the health system.

Number all pages, reflecting the total number of
pages as well: page 1 of 5, 2 of 5, etc. Put the policy
title/number in the header of each page.
Note other policies on a similar subject that may be For example, the disclosure policy should crossuseful at the end of the policy, for cross-reference reference adverse event reporting policy, the patient
purposes. Incorporate any related form(s) or
complaint/grievance policy, and the bill
computer screen images referred to in a policy
hold/adjustment policy. Also for example, the
EMTALA transfer form should be a part of the
EMTALA policy.
Cite specific federal or state statute(s) that are the It may also be helpful to put a URL link to those
basis for a policy or procedure with any other
statutes.
references.
At the end of the document, note evidence-based Noting the referenced resources in each policy has
resources referred to when developing the policy. both advantages and disadvantages. The
advantage is that readers are aware of a
professional source for more information on that
subject. Another advantage is that it demonstrates
the policy was developed with awareness of
recognized professional guidelines and evidencebased best practices. However, potential risks arise
when: a) the organization’s policy differs from the
cited professional guidelines or omits some key
element noted in those guidelines; b) If the cited
professional guideline is updated following issuance
of the policy, and the organization has not updated
the policy accordingly.
Some organizations simply place a list of resources
as an attachment to each policy, so that it is not a Doing so means that if the organization has to
part of the actual, page-numbered policy document. produce the policy during discovery, the list of
resources need not be turned over, since it “was not
part of the policy itself”.
Avoid under-specifying: Put all essential elements in For instance, stating that “X action shall be taken”
the policy.
does not specify which staff member is responsible
for carrying out the task.
If a hospital implements a policy that goes
Avoid developing policies that outline actions that
beyond what is the prevailing practice in the
are more rigorous than the typical “standard of
industry, the organization will be held to the higher
care.”
standard.
Use caution when approving a policy on a specific Doing this implies: a) the cited book is the most
topic or practice that simply states that staff shall
updated authoritative source on that subject; b) the
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Recommendation
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Rationale

adhere to the practices outlined in “ABC Textbook” responsible domain leaders have reviewed the book
(and does not outline the organization’s own steps). from cover to cover and have “endorsed” all of its
contents; c) staff members have ready access to
Citing a reference as the policy may be appropriate that resource (at all times); and d) there is a process
in place to monitor when the ACR issues a revised
in a narrow range of situations. For example, the
version of this manual, so the organization does not
American College of Radiology publishes an
evidence-based, comprehensive “Use of Contrast continue to use guidelines that may have changed.
Media Manual” with regular updates. Rather than
develop its own policies on this subject (which would
likely be shorter and oversimplified when compared
to this manual), a hospital-based radiology
department may wish to endorse the staff’s use of
this manual, with the proviso noted to the right.
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APPENDIX D
EMR Opioid Documentation Template
Opioid documentation in EMR software will be designed for convenience of data extraction to
evaluate physicians, nurse practitioners, and nurses for compliance with the policy. The major
EMR categories will be:
•
•

•

•

•

•

Type of opioid prescription
o Long acting
o Short acting
Case manager nurse, patient/family caregiver, & prescriber
communication
o Yes
• Communication note
o No
Non-pharmacological & alternative options
o Offered
• Documentation of options offered & outcome
o Not offered
• Document why not offered
Patient education
o Yes
• Communication note
o No
• Describe why?
Opioid Reconciliation
o Yes
• Communication note
o No
• Describe why?
o Not applicable
Opioid disposal
o Yes
• Communication note
o No
• Describe why?
o Not applicable
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Aim 3: Dissemination of policy and implementation of protocol
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APPENDIX F
Timeline of the DNP Project

Task
Meetings with DNP Project Advisor (ongoing)
Create position & Hire Policy Manager
Download Federal Opioid Regulations
Download State & Local opioid regulations
Build Repository Framework on Sharepoint
Create automatic alerts to be sent to Project lead of deposited regulations
Build Interdisciplinary Project teams
Review federal opioid regulations
Review State & local opioid regulations
Develop policy themes & draft an opioid policy
Interdisciplinary opioid project team meetings - Monthly
Finalize Opioid Policy
Amedisys Policy Committee Approval
Update EMR documentation template
Update Operations Process Manual
Design & Build Policy Education
Send E-mail blast of policy implementation
Web-Ex policy education sessions
Online LMS policy education sessions
On-site policy education
Web-Ex attendance (Outcome Evaluation)
Online LMS policy education attendance (Outcome Evaluation)
On-site policy education attendance (Outcome Evaluation)
EMR Compliance Report (Outcome Evaluation)
Manuscript Submitted to Peer-Reviewed Journal or Conference

Start Date
10/1/18
1/1/19
12/17/19
12/17/19
11/11/19
11/18/19
1/20/20
6/1/20
6/1/20
7/1/20
3/20/20
7/25/20
8/07/20
8/7/20
8/7/20
8/7/20
8/15/20
9/1/20
9/1/20
9/1/20
9/1/20
9/1/20
9/1/20
9/30/20
1/1/21

End Date
1/31/21
4/1/19
1/17/20
1/17/20
11/18/19
11/20/19
3/20/20
6/30/20
6/30/20
7/20/20
11/20/20
8/07/20
8/07/20
8/31/20
8/31/20
8/31/20
8/15/20
11/30/20
11/30/20
11/30/20
11/30/20
11/30/20
11/30/20
12/5/20
1/31/21

Duration
485
90
30
30
7
2
59
30
30
20
240
14
1
25
25
25
1
61
61
61
61
61
61
66
31

